Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

April 15, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
DyskinesiaCerebral Palsy
Interventions
DRUG

Placebo

Capsule, administered once daily orally or via gastrostomy/gastrojejunostomy tube

DRUG

Valbenazine

Capsule, administered once daily orally or via gastrostomy/gastrojejunostomy tube

Trial Locations (38)

1200

Neurocrine Clinical Site, Brussels

10003

Neurocrine Clinical Site, New York

21205

Neurocrine Clinical Site, Baltimore

28006

Neurocrine Clinical Site, Madrid

32561

Neurocrine Clinical Site, Gulf Breeze

32806

Neurocrine Clinical Site, Orlando

33155

Neurocrine Clinical Site, Miami

43205

Neurocrine Clinical Site, Columbus

45229

Neurocrine Clinical Site, Cincinnati

48334

Neurocrine Clinical Site, Farmington Hills

55101

Neurocrine Clinical Site, Saint Paul

56128

Neurocrine Clinical Site, Calambrone

60611

Neurocrine Clinical Site, Chicago

73120

Neurocrine Clinical Site, Oklahoma City

76104

Neurocrine Clinical Site, Fort Worth

77030

Neurocrine Clinical Site, Houston

80045

Neurocrine Clinical Site, Aurora

92123

Neurocrine Clinical Site, San Diego

97239

Neurocrine Clinical Site, Portland

7030000

Neurocrine Clinical Site, Ẕerifin

06905

Neurocrine Clinical Site, Stamford

02115

Neurocrine Clinical Site, Boston

75390-8857

Neurocrine Clinical Site, Dallas

C1060AAF

Neurocrine Clinical Site, Buenos Aires

C1425EFD

Neurocrine Clinical Site, Buenos Aires

70684-831

Neurocrine Clinical Site, Brasília

80250-060

Neurocrine Clinical Site, Curitiba

90035-001

Neurocrine Clinical Site, Porto Alegre

90050-170

Neurocrine Clinical Site, Porto Alegre

3. 20162

Neurocrine Clinical Site, Milan

Unknown

Neurocrine Clinical Site, Aguascalientes

80-389

Neurocrine Clinical Site, Gdansk

30-539

Neurocrine Clinical Site, Krakow

32-600

Neurocrine Clinical Site, Oświęcim

1169-045

Neurocrine Clinical Site, Lisbon

1649-035

Neurocrine Clinical Site, Lisbon

4050-651

Neurocrine Clinical Site, Porto

08038

Neurocrine Clinical Site, Barcelona

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY